1-(4-tert-Butyl-phenyl)-6-chloro-3-(3-methoxy-phenoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-(4-tert-Butyl-phenyl)-6-chloro-3-(3-methoxy-phenoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid
• 英文别名: 1-(4-tert-butylphenyl)-6-chloro-3-(3-methoxyphenoxy)pyrrolo[2,3-b]pyridine-2-carboxylic acid
• 化学式: C₂₅H₂₃ClN₂O₄
• 分子量: 450.922
• InChiKey: BJNDNICODBYMMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,6-二氯烟酸乙酯 在 sodium hydroxide 、 copper diacetate 、 sodium ethanolate 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 40.0h， 生成 1-(4-tert-Butyl-phenyl)-6-chloro-3-(3-methoxy-phenoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists

  摘要：

  A series of novel aryl indole-2-carboxylic acids has been identified as potent selective PPAR gamma modulators. Their chemical synthesis and in vitro activities are discussed. Compound 5 was selected for in vivo testing in the db/db mouse model of type 2 diabetes and resulted in reduction of hyperglycemia at comparable plasma exposure when compared to rosiglitazone. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.002

文献信息

• Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists
  作者：James F. Dropinski、Taro Akiyama、Monica Einstein、Bahanu Habulihaz、Tom Doebber、Joel P. Berger、Peter T. Meinke、Guo Q. Shi

  DOI：10.1016/j.bmcl.2005.08.002

  日期：2005.11

  A series of novel aryl indole-2-carboxylic acids has been identified as potent selective PPAR gamma modulators. Their chemical synthesis and in vitro activities are discussed. Compound 5 was selected for in vivo testing in the db/db mouse model of type 2 diabetes and resulted in reduction of hyperglycemia at comparable plasma exposure when compared to rosiglitazone. (c) 2005 Elsevier Ltd. All rights reserved.